Trials / Terminated
TerminatedNCT04408040
Use of Convalescent Plasma for COVID-19
Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Northside Hospital, Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The plan is to transfuse COVID-19 infected patients with convalescent plasma and observe whether this will result in a significant improvement in clinical outcome in comparison to historical experience.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Convalescent Plasma | 200-425mL convalescent plasma donated by patients previously positive for COVID-19 |
Timeline
- Start date
- 2020-07-14
- Primary completion
- 2021-09-14
- Completion
- 2021-09-14
- First posted
- 2020-05-29
- Last updated
- 2022-11-14
- Results posted
- 2022-11-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04408040. Inclusion in this directory is not an endorsement.